Outcome of Board Meeting

September 21, 2026 To, To, The Listing Department, The Listing Department BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Mumbai – 400001 Bandra (East), Mumbai – 400051 Scrip code: 544889 Symbol: SYMBIOTEC Sub.: Outcome of the Board Meeting of the Company. Ref.: 1. Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”); 2.Our intimation dated September 11, 2026 Dear Sir / Madam, With reference to the captioned subject, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, September 21, 2026, have inter alia considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026 (“unaudited Financial Results”). Enclosed are the Unaudited Financial Results along with Limited Review Reports for your records. (Pursuant to Regulation 47 of the SEBI Listing Regulations, extract of these results will be published in newspapers). The meeting commenced at 03:30 p.m. and concluded at 04:45 p.m. The Trading Window for dealing in Company’s securities shall remain closed until 48 hours from this announcement. The above information is being made available on website of the Company i.e. https://investor.symbiotec.com/performance?tab=quarterly Thanking You. Sincerely, For Symbiotec Pharmalab Limited Salil Jain Company Secretary and Compliance Officer Membership No. A41610 Encl: As above Registered Office & Works: Symbiotec Pharmalab Limited (Formerly known as Symbiotec Pharmalab Pvt. Ltd.) 385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222, Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com CIN: U24232MP2002PLC015293 SR BCC&O LLP 12tFhl oTohRreu, b y 29S enaBpaapMtaaitr g Dad(aWre st) ChartAecrceodu ntants Mumb-4a0i00 2 8I,n dia T:e+ l9212 6 81890 00 IndepenAduednitt Roerv'isRe ewp orotnt h eQ uarterUlnuyad itCeodn soliFidnaatnecdi al Resutlsof t hCeom panPuyrs auntt o thReeg ula3t3 iofot hne S EB(IL iins Ogtbligatainodn s DisclosRueqruei remReenugtlsa)t i01o5n ,sa,s 2amended RevieRwep or tto The BoaorfdD irectors SymbioPtheacr maLlimaibt (efodr merklnoyw na sSy mbioet cPharmaPlriavba tLei mited) I.Weh avree vitehwaeec dc ompaSntyaitneogmfU e nnatu dCiotnesdo lFiidnaatRneecdsi uaollft s SymbiPohtaercm Lailmaib(t foerdm ekrnloywa nsS ymbiPohtaencn ParliavLbai tmei (ttehde) "HoldCionmgp anayni"dt) ss u bsid(itaHhroeil edCsio nmgp aannyid t ssu bsidtioagreitehse r refetraors "e tdGh reo ufoprt" h)qe u aretnedJreu dn3 e02 ,0 2(6t "hSet ateamtetnahtce"hr)ee dw ith, beisnugb mibtytt heHedo ldCionmgp apnuyr stuota hnrete quiroefRm eegnutls3a 3to ift ohne SEB(IL isOtbilnigg aatniDdoi nssc lRoesquurier ements2)0 1Ra5es,ag muelnad(tetidho ens, "LisRteignugl ations"). 2.ThHeo ldCionmgp anMya'nsa geimsre enstp onfsotirhb pelr ee paroaftt hiSeot na teimnent accordantchreee cwoigtnahin mtdei aosnu rpermiennctli apdilodew sin nI ndiAacnc ounting Stand3a4(r,Id nA dS3 4")I ntFeirniamn Rceipaolr ptriensgc"ur nidbSeeerdc t1i3oo3nf t he CompaAnci2te0,s1 a 3sa mendreedwa,id tr he lervualinestss t uheedr eaunnoddt eharec rc ounting princgiepnleerasac lcleypi tnIe ndda inaid n c ompliwaintRchee g ul3a3to ifto hnLe i sting RegulaTthSieto antse.hm abesen eatnp prboyvt ehHdeo lding CBoomaporafDdn i yr'e.scO tuorrs responistsioe b xiplraice tosyns c lounts hiSeot na tebmaesonentod u rre view. 3.Wec onduocutrree dv ioeftw h Set ateimnea nctc ordwainttchhe Se t andoanRr edv iew Engage(mSeRn2Et4)s1 " 0R,e voifIe nwt eFriinma ncialP eIrnfofrobmrytem hIdaen t dieopne ndent Audiotfto hrEe n tiitsys"bu yet dhI en stoifCt huatret Aecrceodu notfIa nndtTisha is.st andard requtihrwaeetsp laann pde rfotrhmre e viteoow b tmaoidne raastseu raastn owc hee tthheer Stateimsfre enoetfm atemriisaslt aAt reemveioneftiw .n tefriinma inncfoiramlac toinosonif sts makiinngq uiprriiemsao,rfp i elrys roenssp onfsofiirnb alneca inaadcl c oumnattitnaegnr ds, applaynianlgy atniodct ahrlee rv iperwo ceAd urreevsii.ess wu bstalnetisinssa c lotlphyea a nn audciotn duicnatc ecdo rwdiatnhc eS toanAn uddairatdniscdn o gn seqduoeennsote tln ya ubslt eo obtaasisnu rtahwnaectw e o uld baewcaoorfame le sl i gnimfiactattnehtmra istg bheit d entiinfied ana udAictc.o rdwiedn ogn loeytx, p raenas usdo ipti nion. Wea lpseor foprrmoecde idanu crceosr wdiattnhhcM eea stCeirr ciuslsaburyte hdSe e curaintdi es ExchaBnogaeor fdI nduinad Reerg ul3a3t(io8of)tn h Lei stRienggu lattoti hoeenx st_e nt applicable. 4.ThSet ateimnecnlttuh fdeie nsa rnecsiouaftll ht sesu bsidFiolariro sifete n st.ir teifteeoAsrn , n exure Ab elow. 5.Basoenod u rre vcioenw duacntpder do cepdeurrfeosar ssm teadit npe adr ag3ra abponhvo et,h ing hacso mteoo uart tetnhtcaiatou nus set sob elitehvtaehta e c compaSntyaitnepgmr eenptia,nr ed accordwaintrchee c ognaintdmi eoans urpermiennctli apilde sid nto hwaenf oreIsnadiida n AccounSttianngd( a'rIAdnSsd' s )p eciufndiSeeerdc t1i3oo3nf t hCeo mpaAncit2e,0s 1 a3s, amendreedaw,di trhe lervualnietss s tuheedr eaunnoddt ehrae crc ountingg enperrianlcilpyles acceipnIt neddhi aans,o t ditshcieln foosrermdea qtuitioobrn ede ids clotseeromdfts h iLeni sting Regulaitnicolnutsdh,mie an ngn ienwr h iicithts o b ed iscloorts heiadctt.o ntaanimyna st erial isstatement. SRB C& c LoL Pa. limliitaebPdia lrittnyew irtsLhhLI iPdp e nNtoiA.tA yB -4318 ReqOdf.f i2c2Ce.a: m aSct reBleot·c.ek 3· r.Fd l oKoorl.k at0a1-67 00 SR C8& COL LP ChartAecrceodu ntants 6.Thea ccompaSntyaitneigmn ecnltuu ndaeusd iintteefidrn iamn rcieaslua lntodst hfienra ncial informianrt eisoponeff c otus ru bsidwihaorisineet sefi,rn iamn rceisaualln otdts h feirn ancial informiantciltouondtr eaeslv eonfuR es8s . 4m8i lltiootnnae,llt o asftse trao xfR s3.. 7m2il lion antdo tcaolm prehleonossfRsi s 2v..e m1 i9l lfiotorhnq e,u a1etnedJreu dn3 e02 ,0 26. Theu naudiintteefdri inma nicnifoarlm afitniaonncr/ie aslua lntodst huenra udfiintaendc ial informofat thiesosuneb sidhiaavnreobi tee ersne vibeywa enday u diatnhodar v bee eanp proved anfudr nishuesbd yt hMteao n ageamneodnu ctro nclounts hiSeot na teimnse ofan rta ,sir te lates tot haef foafit rhesss ueb sidiibsaa rssieoedls oe nls yu cuhn audiintteefdri inma rnecsiauanlldt s othuenra udfiintaendic nifaolr mAactcioortndot.i h niegn formaanetdxi polna ngaitvtieouon sn s byt hMea nagetmheiinnstt ,e firniamn rceisaull ts/finanacrnieoa mtla tietnrofti oharelm ation Group. Oucro nclounts hiSeot na teimnre enstpo efmc att tsetraistnp e adr6 aa b oivnseo mto diwfiietdh respteotc hftei narnecsiuallt si/nfifnoarncmceairtaitlboi ytnf h iMeea dn agement. 7.ThIen AdS f inainncfoiramlao tfti hGoern o fourpt hqeu aretnedMrea dr 3c1h2. 0 2i6n,c liunded theusnea udciotnesdo lIindAdaS ft ienda rnecsihuaallvtn esob te esnu bjteoac nat u doirrt e view anadr teh bea lanficgiunrbgee st wteheaenu difitgeudri enrs e spoeffc utfil nla nyceiaearnl d ed Mac3h1 2,0 2a6n,td h fei gu(ruensa udited/uupnttrohee evn oidfe t wheiqdru)da 1etnedre d Decem3b12e,0r 2 5. FoSr R &B C OCL LP ChartAecrceodu ntants ICAFIi rrme gistnruamtbie3or2n:4 982E/E300003 peArn iJlo banputra Partner MemberNsoh.1i:1p 0 759 UDI2N6:11 0759MVFAZK6262 PlaMcuem:b ai DatSee:p te2m1b2,e0 r2 6 SRB C& COL LP CharteArcecdo untants Anenuxer A (Refertroine p da ragorfaou prrh e rp4o1o fe vednta e) Lios fetn tiitnicelsinu t dheedres seu lts SrN.o .N amoefe ntity Relationship I SymbiPohtaerca mLailmai(btS ePdL ) HoldCionmgo any 2 KnovePah armacePurtiivcaLatilems i tSeudb siodfSi PaLr y (KPPL) 3 SymbiZoetnefPcor lidvL aitmei( tSeZdP L)S ubsiodfSi PaLr y 4 NaviPstLceii m i(tNePdL ) SubsiodfSi PaLr y 5 XinjiSaynmgb ioBtieoct echLniomliotSgeuydb siodfSi PaLr y (XSBL) 6 SymbiBoitoelcoP griicvLsai tmei( tSeBdP L)S ubsiodfSi PaLr y 7 XenamCeodr p. SubsiodfNi PaLr y SymbPlhoatecrm Lallmftlladb Corporaltdee tyn NUumb(eCrI N):U2 [Showing first 8,000 characters — download PDF for full document]